Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03329508 · ClinicalTrials.gov registry record · Phase 3

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

A Phase 3 study of Parkinson Disease and Early Parkinson's Disease, sponsored by Pharma Two B.

Completed
Registry status
Phase 3
Development phase
544
Enrollment target
20
Study locations

NCT03329508: Completed Phase 3 study of Parkinson Disease and Early Parkinson's Disease, sponsored by Pharma Two B.

NCT03329508 is a Phase 3 study of Parkinson Disease and Early Parkinson's Disease that has completed, run by Pharma Two B. The registered enrollment target is 544 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03329508, a Phase 3 study of Parkinson Disease and Early Parkinson's Disease, has completed, sponsored by Pharma Two B.

COMPLETED
Registry status
Phase 3
Development phase
544 participants
Enrollment target
20
Study locations

Study Summary

P2B001 is an investigational drug that comprised of low doses of two drugs, pramipexole and rasagiline, which are both approved drugs and routinely used in standard therapy for Parkinson's disease. The two drugs work in two different mechanisms that help each other, so there is a reason to believe that their combined activity will be better than each individual drug, and that lower doses can be used without losing the therapeutic effect. Thus, the development of P2B001 is intended to provide a combination of low doses of these two drugs, in an improved formulation, that is hoped to be more effective in controlling Parkinson's disease symptoms and with less side effects than each of the drugs taken alone or the current available commercial drugs taken together. In a previously completed clinical trial a significant improvement in Parkinson's disease symptoms was seen in patients treated with P2B001 compared to patients that were treated with placebo. In this phase 3 study , the safety and efficacy of P2B001 will be assessed by comparing P2B001 to its individual components pramipexole and rasagiline. This will be done by monitoring the motor and non-motor symptoms, evaluating responses participants provide on questionnaires relating to Parkinson's disease and quality of life that will be completed on every visit. In addition, this study will also compare P2B001 to a marketed drug of pramipexole ER. Approximately 525 patients will participate in this research study and the participation in this study will last between 14 to 18 weeks.

Primary Outcome

Differences between P2B 0.6/0.75 mg as compared to its individual components in the change of total UPDRS score (defined as sum of parts II and III, scores (0-160). UPDRS- Unified Parkinson's Disease Rating Scale, minimum value is 0 points and maximum value is 160. High score mean worse outcome.

Conditions Studied

Parkinson Disease Early Parkinson's Disease

Interventions

  • DRUG P2B001 0.6/0.75 mg
  • DRUG Rasagiline 0.75 mg
  • DRUG Pramipexole 0.6 mg
  • DRUG Marketed Pramipexole ER

Study Locations (20)

Florida

  • P2B001/003 site Boca Raton - Boca Raton
  • P2B001/003 Site Boca Raton - Boca Raton
  • P2B001/003 study site Jacksonville - Jacksonville
  • P2B001/003 site Miami - Miami
  • P2B001/003 Site Port Charlotte - Port Charlotte
  • P2B001/003 Site Sarasota - Sarasota
  • P2B001/003 Site Tampa - Tampa

Arizona

  • P2B001/003 Site Scottsdale - Scottsdale
  • P2B001/003 study site Scottsdale - Scottsdale

Illinois

  • P2B001/003 site Chicago - Chicago
  • P2B001/003 Site Winfield - Winfield

Arkansas

  • P2B001/003 Study site little Rock - Little Rock

California

  • P2B001 site Los Angeles - Los Angeles

Colorado

  • P2B001 Study site Englewood, - Englewood

Connecticut

  • P2B001 Study Vernon - Vernon

Georgia

  • P2B001/003 Site Augusta - Augusta

Trial Details

FieldValue
Enrollment Target 544 participants
Start Date 2018-01-19
Est. Completion 2021-10-31
Phase Phase 3
Pharma Two B

2 total trials

What the finished NCT03329508 record still lists

NCT03329508 is an interventional study that assigns participants to a tested intervention. The registered 544 participants enrollment target is mid-sized for trials with a published cap, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (90% lower).

The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 4 interventions - of which P2B001 0.6/0.75 mg is the first listed.

NCT03329508 names 20 study sites across 12 states, led by Florida, Arizona, Illinois.

Frequently Asked Questions

What is clinical trial NCT03329508 about?

NCT03329508 is a clinical study titled "A Phase 3 Study With P2B001 in Subjects With Early Parkinson's". P2B001 is an investigational drug that comprised of low doses of two drugs, pramipexole and rasagiline, which are both approved drugs and routinely used in standard therapy for Parkinson's disease. The two drugs work in two different mechanisms that help each other, so there is a reason to believe t...

What is the current status of trial NCT03329508?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 544 participants. The study started on 2018-01-19. Estimated completion is 2021-10-31.

What conditions does trial NCT03329508 study?

This clinical trial studies the following conditions: Parkinson Disease, Early Parkinson's Disease.

What interventions are being tested in trial NCT03329508?

The interventions under investigation include: P2B001 0.6/0.75 mg (DRUG), Rasagiline 0.75 mg (DRUG), Pramipexole 0.6 mg (DRUG), Marketed Pramipexole ER (DRUG).

Who is sponsoring clinical trial NCT03329508?

This trial is sponsored by Pharma Two B, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03329508 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03329508's enrollment target sits among peer trials

544 22nd of 297 higher than 276 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03127761 · 544 participants

    Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

  • NCT04378790 · 544 participants · Phase 3

    A Randomized Trial to Evaluate Sequential vs Simultaneous Patching

  • NCT06118502 · 544 participants · NA

    A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse

  • NCT06170437 · 544 participants · NA

    Smoke-free Home Study in Subsidized Housing

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03329508, the US trial registry maintained by the National Library of Medicine. NCT03329508 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.